Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CNTA |
---|---|---|
09:32 ET | 344 | 8.8 |
09:34 ET | 912 | 8.96 |
09:38 ET | 500 | 8.99 |
09:39 ET | 500 | 8.91 |
09:41 ET | 432 | 8.8 |
09:43 ET | 1000 | 8.7811 |
09:45 ET | 900 | 8.77 |
09:48 ET | 1114 | 8.84 |
09:50 ET | 200 | 8.97 |
09:52 ET | 200 | 8.96 |
09:56 ET | 100 | 8.96 |
09:57 ET | 979 | 8.95 |
09:59 ET | 399 | 8.9 |
10:01 ET | 308 | 8.92 |
10:03 ET | 1200 | 8.8309 |
10:06 ET | 500 | 8.94 |
10:10 ET | 163 | 8.96 |
10:14 ET | 266 | 8.83 |
10:15 ET | 100 | 8.9 |
10:19 ET | 1700 | 8.89 |
10:24 ET | 1413 | 8.9 |
10:26 ET | 1089 | 8.965 |
10:28 ET | 500 | 9 |
10:30 ET | 200 | 9.03 |
10:32 ET | 100 | 8.995 |
10:33 ET | 300 | 9.06 |
10:37 ET | 300 | 9.02 |
10:39 ET | 200 | 9.06 |
10:42 ET | 300 | 9.03 |
10:44 ET | 900 | 9.07 |
10:46 ET | 100 | 9.03 |
10:48 ET | 500 | 9.04 |
10:50 ET | 710 | 9.03 |
10:51 ET | 200 | 9.04 |
10:53 ET | 195 | 9.11 |
10:57 ET | 300 | 9.09 |
11:02 ET | 113 | 9.13 |
11:04 ET | 500 | 9.12 |
11:13 ET | 300 | 9.06 |
11:18 ET | 100 | 9.055 |
11:20 ET | 200 | 9.035 |
11:22 ET | 1730 | 9.04 |
11:24 ET | 1653 | 9.03 |
11:26 ET | 200 | 9.045 |
11:29 ET | 2244 | 9 |
11:31 ET | 6000 | 8.975 |
11:33 ET | 1200 | 8.97 |
11:36 ET | 1211 | 8.99 |
11:45 ET | 100 | 8.99 |
11:49 ET | 1228 | 9 |
11:54 ET | 100 | 9 |
11:58 ET | 100 | 9.03 |
12:00 ET | 400 | 9.01 |
12:02 ET | 100 | 9.035 |
12:07 ET | 100 | 9.05 |
12:16 ET | 300 | 9.04 |
12:20 ET | 100 | 9.06 |
12:23 ET | 100 | 9.07 |
12:27 ET | 200 | 9.04 |
12:32 ET | 200 | 9.055 |
12:36 ET | 100 | 9.09 |
12:38 ET | 100 | 9.09 |
12:39 ET | 100 | 9.12 |
12:50 ET | 100 | 9.14 |
12:54 ET | 100 | 9.14 |
12:56 ET | 200 | 9.11 |
12:57 ET | 100 | 9.17 |
12:59 ET | 100 | 9.14 |
01:01 ET | 100 | 9.17 |
01:06 ET | 100 | 9.16 |
01:08 ET | 600 | 9.11 |
01:17 ET | 600 | 9.08 |
01:24 ET | 100 | 9.12 |
01:32 ET | 300 | 9.12 |
01:33 ET | 100 | 9.15 |
01:35 ET | 100 | 9.16 |
01:37 ET | 200 | 9.13 |
01:46 ET | 300 | 9.2 |
01:48 ET | 100 | 9.192 |
01:50 ET | 100 | 9.2 |
01:55 ET | 100 | 9.2 |
02:00 ET | 898 | 9.14 |
02:04 ET | 1810 | 9.12 |
02:06 ET | 200 | 9.13 |
02:09 ET | 2601 | 9.1 |
02:11 ET | 100 | 9.09 |
02:18 ET | 700 | 9.125 |
02:20 ET | 200 | 9.15 |
02:24 ET | 100 | 9.13 |
02:26 ET | 300 | 9.13 |
02:27 ET | 943 | 9.08 |
02:29 ET | 100 | 9.095 |
02:31 ET | 100 | 9.1 |
02:33 ET | 100 | 9.12 |
02:38 ET | 100 | 9.11 |
02:40 ET | 200 | 9.15 |
02:44 ET | 1616 | 9.11 |
02:56 ET | 300 | 9.12 |
03:00 ET | 200 | 9.11 |
03:02 ET | 400 | 9.09 |
03:07 ET | 200 | 9.1 |
03:09 ET | 200 | 9.095 |
03:12 ET | 100 | 9.075 |
03:18 ET | 2411 | 9.09 |
03:20 ET | 1141 | 9.085 |
03:21 ET | 800 | 9.11 |
03:23 ET | 100 | 9.1 |
03:34 ET | 593 | 9.13 |
03:39 ET | 200 | 9.12 |
03:41 ET | 100 | 9.14 |
03:43 ET | 100 | 9.15 |
03:50 ET | 400 | 9.12 |
03:52 ET | 842 | 9.13 |
03:54 ET | 600 | 9.13 |
03:56 ET | 1039 | 9.12 |
03:57 ET | 6730 | 9.03 |
03:59 ET | 1500 | 9.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Centessa Pharmaceuticals PLC | 988.0M | -6.4x | --- |
Pharvaris NV | 896.0M | -6.8x | --- |
Cullinan Therapeutics Inc | 932.5M | -5.2x | --- |
Autolus Therapeutics PLC | 917.8M | -3.1x | --- |
Enliven Therapeutics Inc | 1.1B | -11.7x | --- |
Tyra Biosciences Inc | 898.4M | -10.6x | --- |
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $988.0M |
---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 113.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.42 |
Book Value | $2.39 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | 144.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,312.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.